H5N1 Insiders Speak Out

NSABB and Congress members voice their opinions about the new developments in the H5N1 research debate.

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Ron Fouchier, who leads one of the controversial H5N1 research projects (far left) with Bruce Alberts, Editor-in-Chief of Science and Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID) at the American Society of Microbiologists biodefense meeting held on February 29. FLICKR, MICROBE WORLD

Since the US government asked the National Science Advisory Board for Biosecurity (NSABB) last week to reconsider revised manuscripts of controversial H5N1 research, which contain “new” and "clarified older data" not evaluated previously by the NSABB, several members of the security board, as well as a senior US congressman, have spoken out about the unfolding events.

Lynn Enquist, molecular biologist at Princeton University and one of the 23 voting members of the NSABB panel told ScienceInsider that the H5N1 experiments carried out independently by research teams at Erasmus Medical Center in Rotterdam, the Netherlands, and the University of Wisconsin, Madison, clearly fall under the classification of “experiments of concern” delineated by the highly influential 2003 National Academies report on biotechnology and terrorism.

“They not only ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Cristina Luiggi

    This person does not yet have a bio.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio